Disease · MONDO_0005186
cocaine dependence
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. cocaine dependence. Diseases, record MONDO_0005186. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005186
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Cocaine dependence (disorder), Cocaine dependence, unspecified (disorder), Cocaine dependence, unspecified use, Cocaine drug dependence NOS (disorder), Mental and behavioral disorder due to use of cocaine: dependence syndrome (disorder), cocaine addiction
- Open Targets
- Highest stage of its drugs
- Phase 3, for 8 of its 105 drugs, from ClinicalTrials.gov and TTD
- Open Targets
Drugs105
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| MODAFINIL | CHEMBL1373 | Small molecule | Phase 3 | ClinicalTrials.gov | 17 | 17 | 17 | Drugs and targets |
| NALTREXONE | CHEMBL19019 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| TOPIRAMATE | CHEMBL220492 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| SELEGILINE | CHEMBL972 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| BIPERIDEN | CHEMBL1101 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PERGOLIDE | CHEMBL531 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CITICOLINE | CHEMBL1231700 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ECOPIPAM | CHEMBL298406 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| AMPHETAMINE | CHEMBL405 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 6 | 6 | 4 | Drugs and targets |
| DEXTROAMPHETAMINE | CHEMBL612 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
1 to 10 of 105
See all 105 drugsTargets128
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SLC6A2 | Monoamine transporter | 15 | Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent | Phase 2/3 | https://conductscience.org/library/genes/6530 | Drugs and targets |
| SLC6A3 | Monoamine transporter | 11 | Dopamine transporter inhibitor; Dopamine transporter releasing agent; Monoamine transporter inhibitor | Phase 3 | https://conductscience.org/library/genes/6531 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 7 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 7 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 7 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 7 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 7 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 7 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SCN5A | Sodium channel alpha subunit | 7 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6331 | Drugs and targets |
| SCN7A | Sodium channel alpha subunit | 7 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6332 | Drugs and targets |
1 to 10 of 128
See all 128 targetsTrials192
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01402492 | Cocaine Use Reduction With Buprenorphine | Phase 2/3 | 302 | 2021-10-29 | Cocaine Dependence | BUPRENORPHINE, NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT00685178 | Clinical Trial of Topiramate for Cocaine Addiction | Phase 2 | 250 | 2017-07-11 | Cocaine Dependence | TOPIRAMATE | Its record names the disease | ClinicalTrials.gov |
| NCT00129285 | Modafinil Treatment for Cocaine-Dependent Individuals | Phase 2 | 210 | 2018-05-08 | Cocaine-Related Disorders | MODAFINIL | Its record names the disease | ClinicalTrials.gov |
| NCT01281202 | Vigabatrin for the Treatment of Cocaine Dependency | Phase 2/3 | 207 | 2016-02-23 | Cocaine Addiction, Cocaine Dependence | VIGABATRIN | Its record names the disease | ClinicalTrials.gov |
| NCT00611130 | Vigabatrin for Treatment of Cocaine Dependence | Phase 2 | 186 | 2012-06-12 | Cocaine Dependence | VIGABATRIN | Its record names the disease | ClinicalTrials.gov |
| NCT01822587 | Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving | Phase 2 | 181 | 2019-12-17 | Cocaine Addiction | PROPRANOLOL | Its record names the disease | ClinicalTrials.gov |
| NCT01704196 | A Multi-Center Trial of Nepicastat for Cocaine Dependence | Phase 2 | 179 | 2017-05-18 | Cocaine Dependence | NEPICASTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00167245 | Topiramate for Alcohol and Cocaine Dependence | Phase 2 | 170 | 2014-09-01 | Alcoholism, Cocaine Dependence | TOPIRAMATE | Its record names the disease | ClinicalTrials.gov |
| NCT01811940 | Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence | Phase 2/3 | 169 | 2018-10-12 | Cocaine Dependence | AMPHETAMINE, TOPIRAMATE | Its record names the disease | ClinicalTrials.gov |
| NCT00142818 | Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence | Phase 2 | 164 | 2014-08-29 | Alcohol-Related Disorders, Alcoholism, Cocaine-Related Disorders | MODAFINIL, NALTREXONE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 192
See all 192 trialsComparisons in its trials91
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| CPP-109 Vigabatrin Tablets vs Matching Placebo: Abstinence | 5 of 103 | 9 of 104 | 207 | NCT01281202 | Trial comparisons |
| CPP-109 Vigabatrin Tablets vs Placebo: serious adverse events | 6 of 103 | 3 of 104 | 207 | NCT01281202 | Trial comparisons |
| CPP-109 Vigabatrin Tablets, 500 mg vs Matching Placebo Tablets: Proportion of Subjects in Each Treatment Group Abstinent During the Last 2 Weeks of Treatment. | 7 of 92 | 5 of 94 | 186 | NCT00611130 | Trial comparisons |
| CPP-109 Vigabatrin Tablets, 500 mg vs Matching Placebo Tablet: serious adverse events | 6 of 92 | 0 of 94 | 186 | NCT00611130 | Trial comparisons |
| Nepicastat vs Placebo: Reduction in Use (Weeks 1 - 11) | 13 of 90 | 20 of 89 | 179 | NCT01704196 | Trial comparisons |
| Nepicastat vs Placebo: Abstinence (Weeks 10 - 11) | 4 of 90 | 7 of 89 | 179 | NCT01704196 | Trial comparisons |
| Nepicastat vs Placebo: serious adverse events | 8 of 90 | 2 of 89 | 179 | NCT01704196 | Trial comparisons |
| Topiramate vs Placebo: deaths from any cause | 0 of 83 | 0 of 87 | 170 | NCT00167245 | Trial comparisons |
| Topiramate vs Placebo: serious adverse events | 0 of 83 | 0 of 87 | 170 | NCT00167245 | Trial comparisons |
Varenicline vs Placebo: Number of Participants Who Report no Cocaine Use and Have no Cocaine Positive Urine Drug Screens in the Chantix Group Versus the Placebo Group Comparator During the Last Three Weeks of the Trial | 6 of 80 | 7 of 76 | 156 | NCT01680887 | Trial comparisons |
1 to 10 of 91
See all 91 comparisons in its trialsPapers from its trials57
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005186
GET https://conductscience.org/api/diseases/v1/MONDO_0005186/drugs?page=2